Lea Querques1,2, Mariacristina Parravano2, Riccardo Sacconi1,3, Alessandro Rabiolo1, Francesco Bandello1, Giuseppe Querques4. 1. Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy. 2. G. B. Bietti Foundation-IRCCS, Rome, Italy. 3. Eye Clinic, Department of Neurological and Movement Sciences, University of Verona, Verona, Italy. 4. Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy. giuseppe.querques@hotmail.it.
Abstract
AIMS: To investigate the effect of dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME). METHODS: Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled. Patients underwent a comprehensive ocular examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography, ultra-widefield (UWF) retinography and UWF fluorescein angiography (UWFA). RESULTS: Nine eyes of seven consecutive patients (five males; mean age 66.4 ± 6.7 years) were enrolled. Mean duration of DR was 12.3 ± 8.4 years. Mean interval between UWFA acquisitions was 12.1 ± 2.1 weeks, and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Mean pre- and post-injection BCVA was 0.30 ± 0.20 and 0.21 ± 0.14 logMAR (p = 0.06), respectively. Mean pre- and post-injection central macular thickness was 449.8 ± 92.5 and 356.3 ± 52.4 μm (p = 0.03), respectively. Mean pre- and post-injection ischemic index was 24.0 ± 25.0 and 9.8 ± 12.1% (p = 0.0427), respectively. CONCLUSIONS: Intravitreal dexamethasone implant reduces peripheral retina ischemia in patients with DR.
AIMS: To investigate the effect of dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME). METHODS:Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled. Patients underwent a comprehensive ocular examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography, ultra-widefield (UWF) retinography and UWF fluorescein angiography (UWFA). RESULTS: Nine eyes of seven consecutive patients (five males; mean age 66.4 ± 6.7 years) were enrolled. Mean duration of DR was 12.3 ± 8.4 years. Mean interval between UWFA acquisitions was 12.1 ± 2.1 weeks, and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Mean pre- and post-injection BCVA was 0.30 ± 0.20 and 0.21 ± 0.14 logMAR (p = 0.06), respectively. Mean pre- and post-injection central macular thickness was 449.8 ± 92.5 and 356.3 ± 52.4 μm (p = 0.03), respectively. Mean pre- and post-injection ischemic index was 24.0 ± 25.0 and 9.8 ± 12.1% (p = 0.0427), respectively. CONCLUSIONS: Intravitreal dexamethasone implant reduces peripheral retina ischemia in patients with DR.
Authors: Paolo S Silva; Dennis M Marcus; Danni Liu; Lloyd Paul Aiello; Andrew Antoszyk; Michael Elman; Scott Friedman; Adam R Glassman; Joseph M Googe; Lee Merrill Jampol; Daniel F Martin; Michele Melia; Carin M Preston; Charles C Wykoff; Jennifer K Sun Journal: JAMA Ophthalmol Date: 2022-10-01 Impact factor: 8.253
Authors: Akiyoshi Uemura; Marcus Fruttiger; Patricia A D'Amore; Sandro De Falco; Antonia M Joussen; Florian Sennlaub; Lynne R Brunck; Kristian T Johnson; George N Lambrou; Kay D Rittenhouse; Thomas Langmann Journal: Prog Retin Eye Res Date: 2021-02-25 Impact factor: 21.198
Authors: Luke Nicholson; Roxanne Crosby-Nwaobi; Joana C Vasconcelos; A Toby Prevost; Jayashree Ramu; Amy Riddell; James W Bainbridge; Philip G Hykin; Sobha Sivaprasad Journal: Invest Ophthalmol Vis Sci Date: 2018-08-01 Impact factor: 4.799